Batoprotafib

DB19137InvestigationalSmall molecule

Batoprotafib is under investigation in clinical trial NCT04330664 (Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)).

Mechanism: Pharmacologically active on Tyrosine-protein phosphatase non-receptor type 11
Curator reviewed
Formula / weight: C₁₈H₂₄ClN₇OS · 421.95 g/mol (avg)
Also known as: (3s,4s)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)sulfanyl)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro(4.5)decan-4-amine · PTPN11 inhibitor TNO155 · SHP2 inhibitor TNO155
Code names: TNO-155

Resolves to

Compound

Structure

InChIKeyUCJZOKGUEJUNIO-IINYFYTJSA-NSMILESC[C@@H]1OCC2(CCN(CC2)C2=CN=C(SC3=CC=NC(N)=C3Cl)C(N)=N2)[C@@H]1N

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Batoprotafib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.